Trial Profile
A phase 1 study of Eribulin ORA for treatment of cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Cancer
- Focus Adverse reactions
- 06 Nov 2018 New trial record
- 29 Oct 2018 According to an media release, the FDA has allowed the IND application for the oral formulation of Eribulin. The company expects to initiate this study in first half of 2019.